View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
July 23, 2018

Sanofi and Regeneron’s cemiplimab will be sixth marketed PD-1/PD-L1 inhibitor

Approval of Sanofi and Regeneron’s cemiplimab (REGN-2810), a programmed cell death protein 1 (PD-1) checkpoint inhibitor, is expected in cutaneous squamous cell carcinoma (CSCC) from the FDA in October 2018 and the European Medicines Agency (EMA) in Q1 2019.

By GlobalData Healthcare

Approval of Sanofi and Regeneron’s cemiplimab (REGN-2810), a programmed cell death protein 1 (PD-1) checkpoint inhibitor, is expected in cutaneous squamous cell carcinoma (CSCC) from the FDA in October 2018 and the European Medicines Agency (EMA) in Q1 2019.

Five PD-1 or programmed cell death ligand 1 (PD-L1) inhibitors – Bristol-Myers Squibb’s (BMS) Opdivo (nivolumab), Merck Sharp & Dohme’s (MSD’s) Keytruda (pembrolizumab), Roche’s Tecentriq (atezolizumab), AstraZeneca’s Imfinzi (durvalumab), and Pfizer and Merck KGaA’s Bavencio (avelumab) – are already approved in a growing number of indications, leaving Sanofi and Regeneron lagging behind their big pharma competitors.

Sanofi and Regeneron are seeking to begin their campaign in less crowded indications by aiming for a first approval in CSCC, which does not yet have any marketed checkpoint inhibitors.

Pivotal data from the Phase II, single-arm EMPOWER-CSCC 1 study in metastatic CSCC and locally advanced patients who are not candidates for surgery, as well as from the CSCC expansion cohorts of the Phase I trial, have been filed with the US and European regulatory agencies. Approximately 50% of patients in both studies achieved complete or partial responses, and the estimated 12-month progression-free survival and overall survival were 53% and 81%, respectively. These data are likely to result in approval for cemiplimab, since responses with chemotherapy, the current standard of care, are moderate and there are no approved treatments for patients once surgery is no longer an option.

Cemiplimab would face challenges in successfully eroding market share from other products if it entered the market as a monotherapy in indications where Keytruda, Opdivo and the other checkpoint agents are already approved. These challenges are reflected in Sanofi’s clinical trial program, which could allow the company first-mover advantage in a number of other indications that have also not yet seen the entry of checkpoint agents. Cemiplimab is in Phase III development for cervical cancer and basal cell carcinoma, as well as Phase II development for other cancers including glioblastoma multiforme, ovarian and prostate cancers, and acute lymphocytic leukemia.

Cell & Gene Therapy Coverage on Pharmaceutical Technology supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy

By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU